CASI Pharmaceuticals Inc. (CASI)

Oncology Corporate Profile

Stock Performance

1.0000
-0.0500

HQ Location

9620 Medical Center Drive, Suite 300
Rockville, MD 20850

Company Description

CASI is a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China.

Website: http://www.casipharmaceuticals.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ENMD-2076aurora A/angiogenic kinase inhibitorFibrolamellar CarcinomaII
ENMD-2076aurora A/angiogenic kinase inhibitorOvarian cancerII
ENMD-2076aurora A/angiogenic kinase inhibitorSarcomaII
ENMD-2076aurora A/angiogenic kinase inhibitorTriple negative Breast cancerII

View additional information on product candidates here »

Source: http://www.casipharmaceuticals.com

Recent News Headlines

7/25/2017 12:20 am

7/25/2017 12:20 am

7/25/2017 12:20 am

5/30/2017 12:17 am

5/30/2017 12:17 am

5/30/2017 12:17 am

5/18/2017 12:17 am

5/18/2017 12:17 am

5/18/2017 12:17 am

5/17/2017 12:17 am

5/15/2017 12:17 am

5/15/2017 12:17 am

5/15/2017 12:17 am

4/23/2017 12:17 am

4/14/2017 12:17 am

CASI Pharmaceuticals Reports 2016 Fourth Quarter And Full Year Financial Results

3/31/2017 11:00 am

[PR Newswire] - ROCKVILLE, Md., March 31, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, ...

CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting

3/28/2017 11:00 am

[PR Newswire] - ROCKVILLE, Md., March 28, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, ...

CASI Pharmaceuticals' Import Drug Registration Application For EVOMELA® Accepted For Review By CFDA

12/5/2016 12:00 pm

[PR Newswire] - ROCKVILLE, Md., Dec. 5, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announced today that China's Food and Drug Administration (CFDA) has accepted for review the Company's import drug registration application for EVOMELA® (melphalan) for Injection. CASI's China rights to EVOMELA (melphalan) for Injection was previously licensed from its partner Spectrum Pharmaceuticals, Inc. along with two other commercial-stage Spectrum drugs, MARQIBO® and ZEVALIN®. EVOMELA received U.S. FDA approval earlier this year for multiple myeloma patients as a high-dose conditioning treatment prior to autologous stem cell transplantation (ASCT) and as palliative treatment for patients who are not candidates for oral therapy. It was launched in the U.S. this year by Spectrum.